the cells are activated in the presence of either or both interferon-γ and IL-2 or anti-Il-4 antibody or αB7.2 mAb or TGF-β, whereby cells differentiate into Th1 cells; and

(c) in the absence of exogenous Il-2, inducing cell proliferation and expanding the cells under conditions that produce at least about 10^{10} cells/liter of a homogeneous population of Th1 cells, wherein: a homogeneous population of Th1 cells comprises greater than about 50% Th1 cells; and

the resulting cells do not require co-infusion of Il-2 for activity.

29. (Amended) The method of claim 22, wherein anti-IL-4 monoclonal antibodies are also present during activation.

155. (Amended) A method for generating clinically relevant numbers of Th1 cells for autologous cell therapy, comprising:

(a) collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;

(b) treating the cells to induce differentiation of mononuclear cells into Th1 cells, wherein the cells are treated with either or both interferon-γ and IL-2, or anti-Il-4 antibody or αB7.2 mAb or TGF-β to induce differentiation of Th1 cells; and

(c) contacting the resulting differentiated cells with two or more different activating proteins specific for cell surface proteins present on the cells in an amount sufficient to induce *ex vivo* cell expansion, whereby clinically relevant numbers of cells for autologous cell therapy are generated, wherein the contacting is effected in the absence of exogenous IL-2.

157. (Amended) The method of claim 155, wherein the treating step occurs in the absence of exogenous cytokines.

170. (Amended) The method of claim 155, wherein the expanded cells are predominantly Th1 cells.